David S Dickens

List of Publications by Year
in descending order

36	857	687363 13	477307 29
papers	citations	h-index	g-index

36	36	36	1128
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 2094-2101.	1.6	269
2	6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 2014, 124, 2345-2353.	1.4	164
3	Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. Journal of Oncology Practice, 2016, 12, e388-e395.	2.5	63
4	Cyclooxygenase-2 Expression in Pediatric Sarcomas. Pediatric and Developmental Pathology, 2002, 5, 356-364.	1.0	49
5	Cyclooxygenase-2 Expression Does Not Correlate With Outcome in Osteosarcoma or Rhabdomyosarcoma. Journal of Pediatric Hematology/Oncology, 2003, 25, 282-285.	0.6	38
6	Comparing pediatric deaths with and without hospice support. Pediatric Blood and Cancer, 2010, 54, 746-750.	1.5	34
7	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Childrenâ€™s Oncology Group study. Blood, 2017, 129, 1919-1926.	1.4	32
8	SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities. Journal of Clinical Oncology, 2021, 39, 3778-3788.	1.6	28
9	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group Study AALL03N1. Journal of Clinical Oncology, 2017, 35, 1730-1736.	1.6	26
10	Medication prior authorization in pediatric hematology and oncology. Pediatric Blood and Cancer, 2017, 64, e26339.	1.5	20
11	Effect of Combined Cyclooxygenase-2 and Matrix Metalloproteinase Inhibition on Human Sarcoma Xenografts. Journal of Pediatric Hematology/Oncology, 2003, 25, 709-714.	0.6	17
12	Surveillance of Hospital-Acquired Central Lineâ€“Associated Bloodstream Infections in Pediatric Hematology-Oncology Patients Lessons Learned, Challenges Ahead. Infection Control and Hospital Epidemiology, 2013, 34, 315-320.	1.8	17
13	Building Competence in Pediatric End-Of-Life Care. Journal of Palliative Medicine, 2009, 12, 617-622.	1.1	16
14	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature Communications, 2016, 7, 10647.	12.8	15
15	Successful Treatment of an Unresectable Choroid Plexus Carcinoma in a Patient With Li-Fraumeni Syndrome. Journal of Pediatric Hematology/Oncology, 2005, 27, 46-49.	0.6	11
16	Barriers to Medication Access in Pediatric Oncology in the United States. Journal of Pediatric Hematology/Oncology, 2019, 41, 286-288.	0.6	10
17	Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network National Clinical Trials Network Supportive Care Cancer Clinical Trial. Journal of Adolescent and Young Adult Oncology, 2022, 11, 117-121.	1.3	8
18	New Roles for Mononuclear Phagocytes in Cancer Biology. Journal of Pediatric Hematology/Oncology, 2008, 30, 584-591.	0.6	6

#	Article	IF	Citations
19	Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Instituteâ€“Designated Community Oncology Research Programs. JCO Oncology Practice, 2020, 16, e1060-e1066.	2.9	6
20	Reducing sedated lumbar punctures in pediatric patients with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e29272.	1.5	4
21	Therapeutic Strategies for Targeting Mononuclear Phagocytes in Cancer. Journal of Pediatric Hematology/Oncology, 2009, 31, 14-17.	0.6	3
22	Exploring Readiness to Engage in Difficult Discussions with Adolescents Living with Advanced Cancer. Biology of Blood and Marrow Transplantation, 2016, 22, S115-S116.	2.0	3
23	WD Repeat Domain 1 (WDR1) Deficiency Presenting as a Cause of Infantile Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, e113-e117.	1.8	3
24	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. Blood, 2015, 126, 82-82.	1.4	3
25	Does Body Mass Index (BMI) during Maintenance Influence Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL)? Results from COG-AALL03N1. Blood, 2021, 138, 213-213.	1.4	3
26	Characterizing academic performance in pediatric acute lymphoblastic leukemia with populationâ€based achievement tests. Cancer Reports, 2022, 5, e1560.	1.4	2
27	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse â€“ a Children's Oncology Group (COG) Study (AALL03N1). Blood, 2012, 120, 882-882.	1.4	2
28	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Childrenâ€™s Oncology Group (COG) study AALL03N1.. Journal of Clinical Oncology, 2014, 32, 10013-10013.	1.6	2
29	Characteristics of pediatric chemotherapy medication errors in a national error reporting database. Cancer, 2008, 112, 445-446.	4.1	1
30	â€œI Wouldn't Do That if I Were Youâ€â€”The Power of Regret When Treating the Incurable. Journal of Clinical Oncology, 2009, 27, 1528-1528.	1.6	1
31	Wearable Monitors Facilitate Exercise in Adult and Pediatric Stem Cell Transplant. Exercise and Sport Sciences Reviews, 2021, 49, 205-212.	3.0	1
32	Primum Non Nocere. JAMA Pediatrics, 2006, 160, 1185.	3.0	0
33	Impact of Computerized Prescriber Order Entry on the Incidence of Adverse Drug Events in Pediatric Inpatients. Pediatrics, 2008, 122, 678-678.	2.1	0
34	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2014, 124, 369-369.	1.4	0
35	Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers. Blood, 2014, 124, 2207-2207.	1.4	0
36	Choice architecture for young adult blood donor recruitment â€“ a feasibility study. Psychology, Health and Medicine, 2021, , 1-6.	2.4	0